ban on tirzepatide Compounded GLP-1 ban: What providers need to know FDA ban on compounded tirzepatide:

A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to an 11 percent reduction in body weight after 36 weeks, according to a randomized phase II clinical trial published in Nature Medicine.

Wondering if you can drink coffee on Ozempic

The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.

As GLP-1 medications become more widely available through telehealth, many people are finding it harder to separate solid medical providers from aggressive marketing

GLP-1, short for glucagon-like peptide-1, is a hormone that plays an important role in signaling fullness after eating, helping to curb appetite and support weight management.1 In